More importantly, the assessment of the efficacy of a therapeutic treatment against wild-type dengue in a clinical setting (wt-TH in Table 1, treatment administered < 48 h of the symptoms’ onset) may be hampered by the fact that most compounds already do not show significant antiviral effect in preclinical models after a delayed administration post-infection (therapeutic regimen). This evidence concerns the gene TH and dengue disease.